Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting.

Vasiliki Mittag-RoussouStefan WagenpfeilFrank LammertCaroline S Stokes

Published in: Endocrinology, diabetes & metabolism (2020)

In this real-world observational evaluation of fatty liver monitored noninvasively in patients with type 2 diabetes treated with either SGLT2 or GLP-1, improvements in measures of hepatic steatosis, glucose and weight parameters were observed after 6 months, with significant reductions of intrahepatic lipid contents seen specifically in the SGLT2 subgroup.

Keyphrases

fatty acid
body mass index
adipose tissue
physical activity
molecular docking
weight loss
type diabetes
cross sectional
blood glucose
weight gain
randomized controlled trial
molecular dynamics simulations
newly diagnosed
phase iii
open label